 |
|
Development of a New Once-a-Day Formulation of Methylphenidate for the Treatment of Attention-deficit/Hyperactivity Disorder
Proof-of-Concept and Proof-of-Product Studies
James Swanson, PhD;
Suneel Gupta, PhD;
Andrew Lam, PhD;
Ira Shoulson, MD;
Marc Lerner, MD;
Nishit Modi, PhD;
Elizabeth Lindemulder, PhD;
Sharon Wigal, PhD
Arch Gen Psychiatry. 2003;60:204-211.
Background The duration of action of the immediate-release formulation of methylphenidate hydrochloride is short (3 to 4 hours), and 3 times daily dosing is thought to maximize effectiveness across a 12-hour day. The initial sustained-release formulations of methylphenidate had reduced efficacy compared with immediate-release methylphenidate and were not well accepted. Tachyphylaxis was hypothesized to account for the reduced effects, and an ascending drug delivery pattern was proposed to overcome this acute tolerance.
Methods Children with attention-deficit/hyperactivity disorder were evaluated in a laboratory school to characterize onset and duration of the effect of a variety of methylphenidate regimens. In a proof-of-concept study, an experimental ascending profile was established by an initial bolus followed by small increasing doses of immediate-release methylphenidate in capsules administered every 30 minutes for 8 hours. Two proof-of-product studies of a new oral once-a-day formulation to deliver methylphenidate by an osmotic pump process based on OROS (ALZA Corp, Mountain View, Calif) technology (hereafter referred to "OROS-methylphenidate") were conducted: a pharmacokinetic study and a pharmacodynamic study.
Results The experimental ascending profile matched the effect of the standard regimen of methylphenidate, 3 times daily. In the pharmacokinetic study, OROS-methylphenidate treatment produced a rapid rise followed by increasing plasma concentrations that peaked 7 to 9 hours after administration. In the pharmacodynamic study, OROS-methylphenidate treatment matched the 3 times daily dosing of methylphenidate for onset and duration of efficacy.
Conclusions These studies demonstrate the translation of a basic science finding (acute tolerance to clinical doses of methylphenidate) into clinical application (the selection of a new drug delivery pattern for methylphenidate). This approach produced a new product (OROS-methylphenidate or Concerta), which proved to have the predicted rapid onset (with 1-2 hours) and long duration of efficacy (10-12 hours) after a single administration in the morning.
From the University of California, Irvine, Department of Pediatrics, Child Development Center (Drs Swanson, Lerner, and Wigal); ALZA Corp, Mountain View, Calif (Drs Gupta, Lam, Modi, and Lindemulder); and the Department of Neurology, University of Rochester, Rochester, NY (Dr Shoulson).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS(R) Methylphenidate in Children With ADHD
Faraone et al.
J Atten Disord 2007;11:157-166.
ABSTRACT
Hematologic and Blood Biochemistry Monitoring During Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder: 2-Year, Open-Label Study Results
Wigal et al.
Pediatrics 2007;120:e120-e128.
ABSTRACT
| FULL TEXT
Single-Dose Pharmacokinetics of Multilayer-Release Methylphenidate and Immediate-Release Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder
Quinn et al.
J Clin Pharmacol 2007;47:760-766.
ABSTRACT
| FULL TEXT
Relative Benefits of Stimulant Therapy With OROS Methylphenidate Versus Mixed Amphetamine Salts Extended Release in Improving the Driving Performance of Adolescent Drivers With Attention-Deficit/Hyperactivity Disorder
Cox et al.
Pediatrics 2006;118:e704-e710.
ABSTRACT
| FULL TEXT
A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
McGough et al.
J Atten Disord 2006;9:476-485.
ABSTRACT
Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder
Wilens et al.
Arch Pediatr Adolesc Med 2006;160:82-90.
ABSTRACT
| FULL TEXT
Managing attention deficit/hyperactivity disorder: unmet needs and future directions
Steer
Arch. Dis. Child. 2005;90:i19-i25.
ABSTRACT
| FULL TEXT
Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom
Secnik et al.
Med Decis Making 2005;25:56-70.
ABSTRACT
Flawed Attention-Deficit/Hyperactivity Disorder Medication Comparison: In Reply
Swanson
Pediatrics 2004;114:1132-1133.
FULL TEXT
Controlled-Release Methylphenidate Improves Attention During On-Road Driving by Adolescents with Attention-Deficit/Hyperactivity Disorder
Cox et al.
J Am Board Fam Med 2004;17:235-239.
ABSTRACT
| FULL TEXT
A Comparison of Once-Daily Extended-Release Methylphenidate Formulations in Children With Attention-Deficit/Hyperactivity Disorder in the Laboratory School (The Comacs Study)
Swanson et al.
Pediatrics 2004;113:e206-216.
ABSTRACT
| FULL TEXT
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow and Swanson
Am. J. Psychiatry 2003;160:1909-1918.
ABSTRACT
| FULL TEXT
Academia and Industry Collaborate to Design a New Stimulant Preparation
JWatch Psychiatry 2003;2003:3-3.
FULL TEXT
Rosack
Psychiatr. News 2003;38:28-28.
FULL TEXT
|
